Submitted by Aspergillus Administrator on 8 September 2014
The new antifungal drug isavuconazole has received approval in Europe for its as a treatment for invasive aspergillosis.
Isavuconazole (drug substance: isavuconazonium sulfate) is an investigational once-daily intravenous and oral broad-spectrum antifungal for the potential treatment of life-threatening invasive fungal infections which predominantly occur in immunocompromised patients such as cancer patients undergoing chemotherapy. It has EU and U.S. orphan drug status for the treatment of invasive aspergillosis and mucormycosis. In the U.S. isavuconazole was granted FDA fast-track status and designated a Qualified Infectious Disease Product (QIDP) for invasive aspergillosis mucormycosis and candidiasis under the U.S. GAIN Act.
News archives
-
Title
Date
